1. Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective.
- Author
-
Levy P, Lemański T, Crossan C, Lefebvre A, Brière JB, Degli Esposti L, and Khan ZM
- Subjects
- Humans, Italy, Medication Adherence, Blood Pressure drug effects, Adult, Middle Aged, National Health Programs economics, Cardiovascular Diseases economics, Cardiovascular Diseases prevention & control, Male, Cost Savings, Female, Aged, Cost-Effectiveness Analysis, Indapamide administration & dosage, Indapamide economics, Perindopril administration & dosage, Perindopril economics, Cost-Benefit Analysis, Hypertension drug therapy, Antihypertensive Agents administration & dosage, Antihypertensive Agents economics, Amlodipine administration & dosage, Amlodipine economics, Drug Combinations, Markov Chains, Quality-Adjusted Life Years
- Abstract
Objective: To evaluate the cost-effectiveness of a single-pill combination (SPC) of perindopril/amlodipine/indapamide versus its free equivalent combination (FEC) in adults with hypertension in Italy., Methods: A Markov model was developed to perform a cost-utility analysis with a lifetime horizon and an Italian healthcare payer's perspective. In the model, the additional effect of the SPC on blood pressure level compared with the FEC was translated into a decreased risk of cardiovascular events and CKD, which was modeled via Framingham risk algorithms. Difference in persistence rates of SPC and FEC were modeled via discontinuation rates., Results: A perindopril/amlodipine/indapamide SPC is associated with lower cost and better health outcomes compared to its FEC. Over a lifetime horizon, it is associated with a 0.050 QALY gain and cost savings of €376, resulting from lower cardiovascular event rates. In the alternative scenario, where different approach for modeling impact of adherence was considered, incremental gain of 0.069 QALY and savings of €1,004 were observed. Results were robust to sensitivity and scenario analyses, indicating that use of this SPC is a cost-effective strategy., Conclusions: The findings indicate that a perindopril/amlodipine/indapamide SPC is a cost-saving treatment option for hypertension in Italy, compared to its FEC.
- Published
- 2024
- Full Text
- View/download PDF